0000899243-20-013929.txt : 20200521
0000899243-20-013929.hdr.sgml : 20200521
20200521210351
ACCESSION NUMBER: 0000899243-20-013929
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200420
FILED AS OF DATE: 20200521
DATE AS OF CHANGE: 20200521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAWES KAREN A
CENTRAL INDEX KEY: 0001261506
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14656
FILM NUMBER: 20903453
MAIL ADDRESS:
STREET 1: 579 BELLEVUE AVE
CITY: NEWPORT
STATE: RI
ZIP: 02840
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REPLIGEN CORP
CENTRAL INDEX KEY: 0000730272
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042729386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7814499560
MAIL ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-04-20
2020-04-22
0
0000730272
REPLIGEN CORP
RGEN
0001261506
DAWES KAREN A
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
WALTHAM
MA
02453
1
0
0
0
Common Stock
2020-04-20
4
M
0
8200
3.30
A
121234
D
Common Stock
2020-04-20
4
S
0
3202
104.98
D
118032
D
Common Stock
2020-04-20
4
S
0
8998
104.42
D
109034
D
Common Stock
2020-04-21
4
M
0
11800
3.30
A
120834
D
Stock Option (Right to Buy)
3.30
2020-04-20
4
M
0
8200
0.00
D
2020-09-16
Common Stock
8200
11800
D
Stock Option (Right to Buy)
3.30
2020-04-21
4
M
0
11800
0.00
D
2020-09-16
Common Stock
11800
0
D
Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020.
$104.98 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.73 to $105.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$104.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.72 to $104.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option is currently exercisable
This Form 4/A amends the Form 4 filed on April 22, 2020 solely to correct the date of the Reporting Person's 10(b)5-1 trading plan.
/s/ Jeffrey P. Leduc (Attorney in Fact)
2020-05-21